2023年欧洲肿瘤内科学会（ESMO）年会将于10月20日-24日在西班牙马德里举行，大会涵盖了肿瘤领域的基础研究、转化研究以及最新的临床研究进展，为临床实践、多学科讨论等提供广阔、卓越的学术平台。
近日，ESMO官网公布了除LBA外的摘要标题。本期小编整理本次批露的乳腺癌领域重磅研究（主要包含MO：mini oral；O：oral）标题，以飨读者。
简短口头报告专场——早期乳腺癌
Mini oral session - Breast cancer, early stage
专场时间：2023年10月23日22:30-24:00（本文时间均为北京时间）
专场主席：Ines V. Vaz Luis (Villejuif, Cedex, France)、Carsten Denkert (Marburg, Germany)、Ava Kwong (Hong Kong, Hong Kong PRC)
专场地点：Bilbao Auditorium - NCC
本专场有3个LBA摘要待确认（TBC）
摘要号：238MO
住所和工作场所长期暴露于空气污染与乳腺癌的发生风险：1990年至2011年法国E3N队列的巢式病例对照研究
Longterm residential and workplace exposure to air pollution and breast cancer risk: a case-control study nested in the French E3N cohort from 1990 to 2011
讲者：Beatrice Fervers (Lyon, France)
摘要号：239MO
体重指数及其变化对早期乳腺癌患者生存结局的影响：BCIRG-001和BCIRG-005研究个体水平数据的汇总分析
Impact of body mass index and its change on survival outcomes in patients with early breast cancer: a pooled analysis of individual-level data from BCIRG-001 and BCIRG-005 trials
讲者：陈海珠（中国，广州）
摘要号：240MO
monarchE研究的探索性分析：ER/PR和Ki-67表达对高风险、HR+/HER2-早期乳腺癌患者预后和预测的影响
Prognostic and predictive impact of estrogen/progesterone receptor (ER/PR), and Ki-67 expression: an exploratory analysis from the monarchE trial in patients with high-risk, HR+, HER2-, early breast cancer (EBC)
讲者：Matthew P. Goetz (Rochester, United States of America)
摘要号：241MO
2008-2020年瑞典以三阴性乳腺癌治疗的HER2阴性/ER零表达和ER低表达患者的特征和真实世界结局
Patient characteristics and real-world outcomes in HER2 negative/ER zero and ER low patients treated as triple-negative breast cancer in Sweden 2008-2020
讲者：Irma Fredriksson (Stockholm, Sweden)
摘要号：242MO
HR+/HER2-早期乳腺癌患者中肿瘤浸润淋巴细胞 (TIL) 与复发评分 (RS) 的相关性-4项前瞻性多中心研究的转化分析
Association of tumor-infiltrating lymphocytes (TILs) with Recurrence Score (RS) in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) early breast cancer (BC) - a translational analysis of four prospective multicentric studies
讲者：Federica Miglietta (Padova, Italy)
摘要号：243MO
浸润性乳腺癌新辅助全身治疗后豁免乳腺癌手术：Ⅱ期多中心前瞻性试验的3年预设主要终点的结局
Omission of breast surgery after neoadjuvant systemic therapy for invasive cancer: three-year preplanned primary-endpoint on a phase 2 multicentre prospective trial
讲者：Henry M. Kuerer (Houston, United States of America)
摘要号：244MO
Ⅱ期“CLEVER”试验：用羟氯喹、依维莫司或组合用药靶向播散休眠肿瘤细胞以预防乳腺癌复发
A Phase II Trial Targeting Disseminated Dormant Tumor Cells with Hydroxychloroquine, Everolimus or the Combination to Prevent Recurrent Breast Cancer (“CLEVER”)
讲者：Angela DeMichele (Philadelphia, United States of America)
优选论文专场——转移性乳腺癌
Proffered Paper session - Breast cancer, metastatic
专场时间：2023年10月21日16:15 - 17:45
专场地点：Barcelona Auditorium - Hall 9
专场主席：Hervé Bonnefoi (Bordeaux, France)、Janice Wing-Hang Tsang (Hong Kong, Hong Kong PRC)
摘要号：376O
随机、Ⅲ期DESTINY-Breast04研究更新的生存结果：德曲妥珠单抗 vs 医生选择的治疗 (TPC) 治疗HER2低表达不可切除和/或转移性乳腺癌患者
Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase 3 DESTINY-Breast04 study
讲者：Shanu Modi (New York, United States of America)
摘要号：377O
DESTINY-Breast (DB) -01、DB-02和DB-03研究的汇总分析：德曲妥珠单抗治疗伴脑转移的HER2阳性转移性乳腺癌患者
A Pooled Analysis of Trastuzumab Deruxtecan (T-DXd) in Patients (pts) With HER2-Positive (HER2+) Metastatic Breast Cancer (mBC) With Brain Metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03
讲者：Sara A. Hurvitz (Santa Monica, United States of America)
摘要号：378O
晚期乳腺癌患者接受阿贝西利和内分泌治疗的持续性-比较MASCC口服药物教学工具（MOATT）与当地常规患者指导的随机IMPACT试验的首次结果
Persistence under abemaciclib and endocrine treatment (ABA+ET) in patients with advanced breast cancer (aBC) – first results of the randomized IMPACT Trial comparing patient coaching with the MASCC Oral Agent Teaching Tool (MOATT) versus local routine patient coaching (LC)
讲者：Manfred K. Welslau (Aschaffenburg, Germany)
摘要号：381O
HS-20089（B7-H4 ADC）治疗晚期实体瘤患者的首项人体/1期试验
First-in-human/phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumors
讲者：张剑（中国，上海）
简短口头报告专场——转移性乳腺癌
Mini oral session - Breast cancer, metastatic
专场时间：2023年10月22日14:30 - 16:00
专场主席：Barbara Pistilli (Villejuif, Cedex, France)、Christoph Thomssen (Halle, Germany)、Hervé Bonnefoi (Bordeaux, France)
专场地点：Bilbao Auditorium - NCC
摘要号：379MO
Ⅰb/Ⅱ期BEGONIA研究的更新结果：Dato-DXd+度伐利尤单抗一线治疗不可切除局部晚期/转移性三阴性乳腺癌患者
Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase 1b/2 study
讲者：Peter Schmid (London, United Kingdom)
摘要号：380MO
SKB264 (MK-2870)用于既往接受过治疗的HR+/HER2-转移性乳腺癌：一项Ⅰ/Ⅱ期单臂、篮式试验的结果
SKB264 (MK-2870) in previously treated hormone receptor-positive (HR+)/ HER2-negative metastatic breast cancer (mBC): results from a phase I/II, single-arm, basket trial
讲者：殷咏梅（中国，南京）
摘要号：382MO
OP-1250[兼具完全雌激素受体拮抗剂(CERAN)和选择性雌激素受体降解剂(SERD)活性的口服小分子药物]治疗晚期或转移性ER+/HER2-乳腺癌患者的Ⅰ/Ⅱ期研究的更新结果
Updated results from the phase 1/2 study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD ) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer
讲者：Nancy U. Lin (Boston, United States of America)
摘要号：383MO
Imlunestrant联合或不联合依维莫司或阿培利司治疗ER+/HER2-晚期乳腺癌：1a/B期EMBER研究的结果
Imlunestrant with or without everolimus or alpelisib, in ER+, HER2- advanced breast cancer (aBC): Results from the phase 1a/b EMBER study
讲者：Komal Jhaveri (New York, United States of America)
摘要号：384MO
氟维司群 vs 阿那曲唑在未经内分泌治疗的激素受体阳性晚期乳腺癌中的最终总生存期分析 (FALCON)
Final overall survival analysis for fulvestrant vs anastrozole in endocrine therapy (ET)-naïve, hormone receptor-positive (HR+) advanced breast cancer (FALCON)
讲者：John Robertson (Nottingham, United Kingdom)
摘要号：385MO
DP303c在既往接受过治疗的HER2阳性晚期实体瘤患者中的多中心、开放标签、剂量递增和扩展研究
A multicenter,open-label,dose escalation and expansion study of DP303c in patients with HER2-positive pre-treated advanced solid tumors
讲者：杜益群（中国，上海）
摘要号：386MO
Trastuzumab duocarmazine与医生选择的疗法治疗既往治疗过的 HER2 阳性转移性乳腺癌：Ⅲ期 TULIP 试验的最终结果
Trastuzumab duocarmazine versus physician's choice therapy in pre-treated HER2-positive metastatic breast cancer: final results of the phase III TULIP trial
讲者：Philippe G. Aftimos (Anderlecht, Belgium)
摘要号：387MO
以患者为中心的晚期乳腺癌分子筛查计划（SOLTI-1903 HOPE）的初步结果
First Results of the SOLTI-1903 HOPE's Patient-Centric Molecular Screening Program in Advanced Breast Cancer
讲者：Tomás Pascual (Barcelona, Spain)
优选论文专场2——基础科学与转化研究Proffered Paper session 2 - Basic Science and Translational research
专场时间：2023年10月21日 20:45 - 22:15
专场主席：Göran Jönsson (Lund, Sweden)、Elin S. Gray (Perth, Australia)
专场地点：Santander Auditorium - Hall 9
摘要号：2232O
早期三阴性乳腺癌患者阿替利珠单抗与肿瘤微环境的相关性：IMpassion031试验的探索性生物标志物分析
Atezolizumab (atezo) and tumour microenvironment in early triple-negative breast cancer (eTNBC): Exploratory biomarker analysis from IMpassion031
讲者：Carlos H. Barrios (Porto Alegre, Brazil)
https://cslide.ctimeetingtech.com/esmo2023/attendee/confcal/session/calendar
排版编辑：肿瘤资讯-Paine
苏公网安备32059002004080号
